FOXO1 inhibition synergizes with FGF21 to normalize glucose control in diabetic mice
Open Access
- 1 July 2021
- journal article
- research article
- Published by Elsevier in Molecular Metabolism
- Vol. 49, 101187
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (R43DK120177)
This publication has 19 references indexed in Scilit:
- Regulation of Glucose Homeostasis by Glucocorticoids2015
- Fibroblast growth factor 21 analogue LY2405319 lowers blood glucose in streptozotocin‐induced insulin‐deficient diabetic mice by restoring brown adipose tissue functionDiabetes, Obesity and Metabolism, 2014
- FoxOs Function Synergistically to Promote Glucose ProductionJournal of Biological Chemistry, 2010
- Discovery of Novel Forkhead Box O1 Inhibitors for Treating Type 2 Diabetes: Improvement of Fasting Glycemia in Diabetic db/db MiceMolecular Pharmacology, 2010
- Hepatic FoxO1 Ablation Exacerbates Lipid Abnormalities during HyperglycemiaJournal of Biological Chemistry, 2010
- Impaired Regulation of Hepatic Glucose Production in Mice Lacking the Forkhead Transcription Factor Foxo1 in LiverCell Metabolism, 2007
- Fibroblast Growth Factor-21 Improves Pancreatic β-Cell Function and Survival by Activation of Extracellular Signal–Regulated Kinase 1/2 and Akt Signaling PathwaysDiabetes, 2006
- FGF-21 as a novel metabolic regulatorJournal of Clinical Investigation, 2005
- The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expressionJournal of Clinical Investigation, 2001
- FKHR Binds the Insulin Response Element in the Insulin-Like Growth Factor Binding Protein-1 Promoter*Endocrinology, 1999